Key result
An automated chromogenic substrate assay of factor X (S 2337) correlated well with Thrombotest, yielding fully concordant therapeutic classification in 76% of patients on warfarin.
Why the study?
Does an automated chromogenic substrate assay of factor X correlate with standard coagulation assays for monitoring oral anticoagulant therapy in patients on warfarin?
Population
25 healthy controls and 375 patients on warfarin therapy (total n=400)
Comparison
Automated amidolytic assay of factor X based on… vs One stage coagulation factor X assay and…
Design
Cross-sectional
Authors
Loading...
Supports further evaluation of chromogenic factor X assay for warfarin monitoring; leaves open prospective outcome validation.
Observational (n=400)
Does an automated chromogenic substrate assay of factor X correlate with standard coagulation assays for monitoring oral anticoagulant therapy in patients on warfarin?
An automated chromogenic substrate assay of factor X correlates well with standard tests and provides concordant clinical classification in 76% of patients on warfarin therapy, suggesting its potential for monitoring maintenance oral anticoagulation.
Erskine et al. (2008) conducted an observational in Patients on Warfarin therapy (n=400). Automated chromogenic substrate assay of factor X (S 2337) vs. Thrombotest and one stage coagulation factor X assay was evaluated on Concordant classification of patients according to proposed therapeutic ranges. An automated chromogenic substrate assay of factor X (S 2337) correlated well with Thrombotest, yielding fully concordant therapeutic classification in 76% of patients on warfarin.
Synapse has enriched one closely related paper. Consider it for comparative context: